Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan

Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 blockade combined with taxane chemotherapy. Although this regimen exhibits high rates of response and disease control in both HR+ and HR− cohorts, s...

Full description

Saved in:
Bibliographic Details
Main Authors: Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
breast cancer
precision oncology
cancer genomics
HER2 antibody-drug conjugates (HER2 ADC)
trastuzumab deruxtecan
neratinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1484750/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items